title: [Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
abstract: The paper presents the results of 2 year maintenance treatment of patients with acute myeloid leukemias using cyclic, rotating and intensive polychemotherapy. Complete remission (CR) was achieved in 22 out of 33 patients with doxorubicin (60 mg/m2; 1-3 days) and cytosine arabinoside (100 mg/m2; 1-7 days). All patients in CR entered into the authors' programme of intensification therapy consisting of two consecutive polychemotherapy cycles, using various combinations of amsacrine, doxorubicin, cytosine arabinoside, etoposide and 6-thioguanine repeated every 3-4 months. The mean survival so far is 18 months (range, 1-52 months). The projected 3-years survival rate in complete remission concerns 33% of the patients treated. Relapses occurred in 50% of the patients, within 10 months (range 1-35 mos.) after CR. Our results indicate that intensive cyclic polychemotherapy markedly prolongs the survival of AML patients. The high frequency of relapses during the first year after CR indicates the necessity to enhance the degree of aggressiveness of treatment shortly after a complete remission has been obtained.
authors.affiliation: Klinika Hematologii Instytutu Chorób Wewnetrznych AM w Poznaniu.
authors.forename: J
authors.initials: J
authors.lastname: Hansz
authors.forename: G
authors.initials: G
authors.lastname: Bajko
authors.forename: T
authors.initials: T
authors.lastname: Woźny
authors.forename: D
authors.initials: D
authors.lastname: Drozdowska
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D013866:Thioguanine
vernacular_title: Wyniki naprzemiennie powtarzanej oraz długotrwałej, intensywnej polichemioterapii w leczeniu podtrzymujçym remisje u chorych na ostre białaczki szpikowe.